Revenue $105.38B, up 7.7% on a year earlier. Medical-Surgical Solutions revenues $2.82B, up 4.4%. U.S. Pharmaceutical and Specialty Solutions revenues $86.80B, down 3.6%. Diluted EPS $5.15 against $6.25.
| Q1 FY27 | Q4 FY26 | Q1 FY26 | Year over year | |
|---|---|---|---|---|
| Revenue | $105.38B | $96.30B | $97.83B | +7.7% |
| Operating income | $1.32B | $2.15B | $1.04B | +27.3% |
| Net income | $614.00M | $1.68B | $784.00M | -21.7% |
| Diluted EPS | $5.15 | $13.69 | $6.25 | |
| Operating cash flow | -$220.00M | $3.42B | -$918.00M | |
| Capital expenditures | -$112.00M | -$111.00M | -$111.00M | |
| Free cash flow | -$332.00M | $3.31B | -$1.03B | |
| Dividend per share | $0.82 | $0.82 | $0.71 |
| Q1 FY27 | Q1 FY26 | Year over year | |
|---|---|---|---|
| Medical-Surgical Solutions revenues | $2.82B | $2.70B | +4.4% |
| U.S. Pharmaceutical and Specialty Solutions revenues | $86.80B | $90.00B | -3.6% |
| Prescription Technology Solutions Revenues | $1.57B | $1.40B | +11.9% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “McKesson (MCK) Q1 FY27 earnings: results and KPIs”, stockatlas.com/companies/MCK/earnings/2027-q1/, data as of 3 November 2026. Links to this page are welcome.
